KalVista Pharmaceuticals (KALV) EBIT Growth (1y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 12.69% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 75.16% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -347.04% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 80.62% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 1.27% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.65% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,386.07% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -33.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -33.46% |
| Apr 30, 2025 | -13.57% |
| Oct 31, 2024 | -54.01% |
| Jul 31, 2024 | -51.98% |
| Apr 30, 2024 | -52.72% |
| Jan 31, 2024 | -23.03% |
| Oct 31, 2023 | -14.92% |
| Jul 31, 2023 | -10.55% |
| Apr 30, 2023 | -18.34% |
| Jan 31, 2023 | -0.98% |
| Oct 31, 2022 | -9.66% |
| Jul 31, 2022 | -34.84% |
| Apr 30, 2022 | -48.60% |
| Jan 31, 2022 | -110.82% |
| Oct 31, 2021 | -84.67% |
| Jul 31, 2021 | -35.12% |
| Apr 30, 2021 | -101.43% |
| Jan 31, 2021 | 0.53% |
| Oct 31, 2020 | -37.59% |
| Jul 31, 2020 | -51.01% |
| Apr 30, 2020 | 20.45% |
| Jan 31, 2020 | -91.05% |
| Oct 31, 2019 | -89.84% |
| Jul 31, 2019 | -36.45% |
| Apr 30, 2019 | -279.25% |
| Jan 31, 2019 | -53.24% |
| Oct 31, 2018 | 17.58% |
| Jul 31, 2018 | -28.53% |
| Apr 30, 2018 | 41.62% |
| Jan 31, 2018 | 46.46% |
| Oct 31, 2017 | -47.50% |
| Jul 31, 2017 | -6.50% |
| Mar 31, 2016 | -33.20% |
| Sep 30, 2015 | -37.30% |
| Jun 30, 2015 | -132.64% |
| Mar 31, 2015 | -164.06% |